Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00429182 · ClinicalTrials.gov registry record · Phase 2
Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00429182: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00429182 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00429182, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn the relationship of high-dose chemotherapy (HDCT) and circulating tumor cells (CTCs) in controlling metastatic breast cancer. The study also will investigate the role of CTCs in breast cancer.
Interventions
- DRUG Cyclophosphamide
- DRUG Carboplatin
- DRUG Thiotepa
- PROCEDURE Stem Cell Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2007-06 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00429182
The ClinicalTrials.gov registry entry for NCT00429182 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT00429182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00429182 about?
NCT00429182 is a clinical study titled "Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer". The goal of this clinical research study is to learn the relationship of high-dose chemotherapy (HDCT) and circulating tumor cells (CTCs) in controlling metastatic breast cancer. The study also will investigate the role of CTCs in breast cancer.
What is the current status of trial NCT00429182?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2007-06. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00429182?
The interventions under investigation include: Cyclophosphamide (DRUG), Carboplatin (DRUG), Thiotepa (DRUG), Stem Cell Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00429182?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.